Q2 2025 Medistim ASA Earnings Call Transcript
Key Points
- Medistim ASA (FRA:MD1) reported a strong second quarter with revenue performance at NOK169.1 million, marking a 16.7% growth over the same quarter last year.
- The Americas region showed impressive performance with a 32.9% currency-neutral growth, accounting for more than 80% of the total nominal revenue increase for the quarter.
- Operating profit increased by 31% over the same quarter last year, achieving a strong EBIT margin of 32%.
- The company made a dividend payout of NOK6 per share, totaling NOK109.6 million, reflecting strong financial health.
- Medistim ASA (FRA:MD1) has strengthened its commercial operations, particularly in the Americas, contributing to the overall growth and success in the first half of 2025.
- EMEA region experienced a decline of 3.6% in sales for the quarter, indicating challenges in this market.
- There was a 20% increase in salary and social expenses due to investments in the commercial organization, impacting overall expenses.
- Other operating expenses increased due to heightened travel activity and expenses related to the PATENT project.
- The company faced a net negative cash flow from financing activities at NOK126 million, primarily due to dividend payouts and share repurchases.
- The launch of the INTUI software platform has been delayed, affecting the anticipated revenue from this new product in the first half of the year.
Good morning, everyone, and welcome to the second quarter and first half 2025 financial results presentations from Medistim. My name is Kari Krogstad. And as usual, I'm joined by my good colleague, CFO, Thomas Jakobsen. And together, we will take you through the results.
And just before we dive into the highlights, we like to start by reminding everyone our track record. This is a great reminder of our goal and ambition, which has been and still is to deliver profitable and growth consistently over time. So we can see quarter variations, but our track record shows that we have succeeded to deliver on this promise over the years.
But now let's look at the second quarter and the second quarter highlights. So I'm very happy and proud to being able to present the second best quarter both for sales and EBIT, and it's actually only beaten by the first quarter this year. So we're seeing revenue performance at NOK169.1 million, which is 16.7% growth over the same quarter last year. And as this slide shows, there is only a slight
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
